Senzime Dirección

Dirección controles de criterios 2/4

El CEO de Senzime's es Philip Siberg , nombrado en May 2023, tiene una permanencia de 1.08 años. compensación anual total es SEK4.61M, compuesta por 55.2% salario y 44.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.59% de las acciones de la empresa, por valor de SEK4.73M. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 3.3 años, respectivamente.

Información clave

Philip Siberg

Chief Executive Officer (CEO)

SEK 4.6m

Compensación total

Porcentaje del salario del CEO	55.2%
Permanencia del CEO	1.2yrs
Participación del CEO	0.6%
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return

Feb 16

We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely

Jan 19

Are Insiders Buying Senzime AB (publ) (STO:SEZI) Stock?

Dec 23

What Kind Of Investors Own Most Of Senzime AB (publ) (STO:SEZI)?

Nov 26

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Philip Siberg en comparación con los beneficios de Senzime?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-SEK 131m
Dec 31 2023	SEK 5m	SEK 3m	-SEK 134m
Sep 30 2023	n/a	n/a	-SEK 138m
Jun 30 2023	n/a	n/a	-SEK 137m
Mar 31 2023	n/a	n/a	-SEK 143m
Dec 31 2022	SEK 450k	n/a	-SEK 133m
Sep 30 2022	n/a	n/a	-SEK 114m
Jun 30 2022	n/a	n/a	-SEK 104m
Mar 31 2022	n/a	n/a	-SEK 86m
Dec 31 2021	SEK 400k	n/a	-SEK 82m
Sep 30 2021	n/a	n/a	-SEK 74m
Jun 30 2021	n/a	n/a	-SEK 66m
Mar 31 2021	n/a	n/a	-SEK 56m
Dec 31 2020	SEK 100k	n/a	-SEK 47m
Sep 30 2020	n/a	n/a	-SEK 41m
Jun 30 2020	n/a	n/a	-SEK 36m
Mar 31 2020	n/a	n/a	-SEK 32m
Dec 31 2019	SEK 100k	n/a	-SEK 33m
Sep 30 2019	n/a	n/a	-SEK 34m
Jun 30 2019	n/a	n/a	-SEK 33m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	SEK 100k	n/a	-SEK 24m
Sep 30 2018	n/a	n/a	-SEK 19m
Jun 30 2018	n/a	n/a	-SEK 16m
Mar 31 2018	n/a	n/a	-SEK 13m
Dec 31 2017	SEK 131k	n/a	-SEK 13m

Compensación vs. Mercado: La compensación total de Philip($USD422.56K) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD245.98K).

Compensación vs. Ingresos: La compensación de Philip ha aumentado mientras la empresa no es rentable.

CEO

Philip Siberg (51 yo)

1.2yrs

Permanencia

SEK 4,614,088

Compensación

Mr. Philip Siberg serves as the Chief Executive Officer of Stille Surgical, Inc. He serves as Chairman of the Board at Acarix AB (publ) since May 11, 2021. He was Co-Founder of Coala-Life Group AB (publ) a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Philip Siberg	Chief Executive Officer	1.2yrs	SEK 4.61m	0.59% SEK 5.3m
Slavoljub Grujicic	Chief Financial Officer	2.5yrs	sin datos	0.021% SEK 187.9k
Johanna Tulkki	Chief Operating Officer	4.5yrs	sin datos	sin datos
Fredrik Norrby	Chief Technology Officer	1.5yrs	sin datos	sin datos
Rianne Waninge	Application Scientist	no data	sin datos	sin datos
Paula Treutiger	Head of Communication & Investor Relations	2.5yrs	sin datos	sin datos
Anders Selin	Executive Vice President of Sales	4.8yrs	sin datos	sin datos
Michael Noble	Vice President Global Marketing	less than a year	sin datos	sin datos
Anders Jacobson	Chief Innovation Officer	8.5yrs	sin datos	0.013% SEK 120.7k
Catrin Molund	Executive Vice President of Business Development	3.5yrs	SEK 163.00k	sin datos
Johanna Faris	Head of Q/RA/S	less than a year	sin datos	0.0013% SEK 11.7k

2.5yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SEZI se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Per Wold-Olsen	Chairman of the Board	less than a year	sin datos	0.34% SEK 3.1m
Goran Brorsson	Independent Director	1.2yrs	SEK 131.00k	0.085% SEK 765.3k
Adam Dahlberg	Vice Chairman of the Board	24.5yrs	SEK 350.00k	5.25% SEK 47.4m
Eva Walde	Independent Director	3.3yrs	SEK 210.00k	sin datos
Sorin Brull	Chief Medical Officer	8.5yrs	SEK 1.31m	3.15% SEK 28.4m
Alfredo Abad-Gurumeta	Member of Scientific Advisory Board	no data	sin datos	sin datos
Bela Fulesdi	Member of Scientific Advisory Board	no data	sin datos	sin datos
Guy Cammu	Member of Scientific Advisory Board	no data	sin datos	sin datos
Hans Boer	Member of Scientific Advisory Board	no data	sin datos	sin datos
Claude Meistelman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jennifer Hunter	Member of Scientific Advisory Board	no data	sin datos	sin datos
Casper Claudius	Member of Scientific Advisory Board	no data	sin datos	sin datos

3.3yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de SEZI se considera experimentada (5.7 años de antigüedad promedio).

Senzime Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Chief Financial Officer recently bought kr67k worth of stock

Chief Financial Officer recently bought kr67k worth of stock

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

Recent updates

Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph System

New minor risk - Profitability

New minor risk - Financial position

Full year 2023 earnings: EPS and revenues miss analyst expectations

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Chief Financial Officer recently bought kr67k worth of stock

Chief Financial Officer recently bought kr67k worth of stock

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Shareholder dilution

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

New major risk - Financial position

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022)

Independent Chairman recently bought kr740k worth of stock

Senzime Receives Approval for Its Pediatric Sensor in Japan

Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021)

Senzime AB (publ) to Report Q1, 2023 Results on May 05, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Third quarter 2022 earnings released: kr0.74 loss per share (vs kr0.31 loss in 3Q 2021)

Less than half of directors are independent

Senzime AB (publ) Provides Earnings Guidance for 2025

Third quarter 2022 earnings released: kr0.74 loss per share (vs kr0.31 loss in 3Q 2021)

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Consensus revenue estimates fall by 34%

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021)

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to kr34.00

Less than half of directors are independent

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Will Senzime (STO:SEZI) Spend Its Cash Wisely?

Price target decreased to kr34.00

Full year 2021 earnings: EPS and revenues miss analyst expectations

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020)

We Think Senzime (STO:SEZI) Can Afford To Drive Business Growth

Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020)

Companies Like Senzime (STO:SEZI) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020)

How Much Of Senzime AB (publ) (STO:SEZI) Do Insiders Own?

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019)

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

New 90-day low: kr21.50

Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return

We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely

New 90-day high: kr25.80

Senzime AB (publ) Gets US Patent for OnZurf Probe

Are Insiders Buying Senzime AB (publ) (STO:SEZI) Stock?

Senzime Lands New Order from South Korea of SEK 1 Million

What Kind Of Investors Own Most Of Senzime AB (publ) (STO:SEZI)?

Third quarter 2020 earnings released: kr0.20 loss per share

Senzime AB (publ) Announces Nomination Committee for 2021 Annual General Meeting

Senzime AB (Publ) Signs an Out-Licensing Agreement with the Moss S.P.A

Senzime AB (publ) Enters into an Exclusive Agreement with the Surgical Company